444 related articles for article (PubMed ID: 29581117)
1. Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.
Zykov IN; Samuelsen Ø; Jakobsen L; Småbrekke L; Andersson DI; Sundsfjord A; Frimodt-Møller N
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29581117
[TBL] [Abstract][Full Text] [Related]
2. Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Lepeule R; Ruppé E; Le P; Massias L; Chau F; Nucci A; Lefort A; Fantin B
Antimicrob Agents Chemother; 2012 Mar; 56(3):1376-81. PubMed ID: 22214774
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
[TBL] [Abstract][Full Text] [Related]
4.
Lepak AJ; Zhao M; VanScoy B; Taylor DS; Ellis-Grosse E; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28396549
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
6. Impact of reflex fosfomycin susceptibility testing on the utilization of carbapenems for definitive extended-spectrum β-lactamase Escherichia coli urinary tract infection treatment.
Deemer K; Grey J; Fronczek C; Marr K
Am J Health Syst Pharm; 2020 Nov; 77(Supplement_4):S105-S110. PubMed ID: 32840305
[TBL] [Abstract][Full Text] [Related]
7. Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.
Senol S; Tasbakan M; Pullukcu H; Sipahi OR; Sipahi H; Yamazhan T; Arda B; Ulusoy S
J Chemother; 2010 Oct; 22(5):355-7. PubMed ID: 21123160
[TBL] [Abstract][Full Text] [Related]
8. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
[TBL] [Abstract][Full Text] [Related]
10. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.
VanScoy BD; McCauley J; Ellis-Grosse EJ; Okusanya OO; Bhavnani SM; Forrest A; Ambrose PG
Antimicrob Agents Chemother; 2015 Dec; 59(12):7170-7. PubMed ID: 26100706
[TBL] [Abstract][Full Text] [Related]
11. Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases.
Bahramian A; Eslami G; Hashemi A; Tabibi A; Heidary M
Acta Microbiol Immunol Hung; 2018 Mar; 65(1):15-25. PubMed ID: 29137487
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of mecillinam against clinical multidrug-resistant Escherichia coli in a murine urinary tract infection model.
Zykov IN; Frimodt-Møller N; Småbrekke L; Sundsfjord A; Samuelsen Ø
Int J Antimicrob Agents; 2020 Feb; 55(2):105851. PubMed ID: 31770624
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli.
Merino-Bohórquez V; Docobo-Pérez F; Sojo J; Morales I; Lupión C; Martín D; Cameán M; Hope W; Pascual Á; Rodríguez-Baño J
Clin Microbiol Infect; 2018 Nov; 24(11):1177-1183. PubMed ID: 29649596
[TBL] [Abstract][Full Text] [Related]
15. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
[TBL] [Abstract][Full Text] [Related]
16. Clinical Appraisal of Fosfomycin in the Era of Antimicrobial Resistance.
Sastry S; Clarke LG; Alrowais H; Querry AM; Shutt KA; Doi Y
Antimicrob Agents Chemother; 2015 Dec; 59(12):7355-61. PubMed ID: 26369978
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility and mechanisms of fosfomycin resistance in extended-spectrum β-lactamase-producing Escherichia coli strains from urinary tract infections in Wenzhou, China.
Bi W; Li B; Song J; Hong Y; Zhang X; Liu H; Lu H; Zhou T; Cao J
Int J Antimicrob Agents; 2017 Jul; 50(1):29-34. PubMed ID: 28456703
[TBL] [Abstract][Full Text] [Related]
18. Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.
Martín-Gutiérrez G; Docobo-Pérez F; Rodriguez-Beltrán J; Rodríguez-Martínez JM; Aznar J; Pascual A; Blázquez J
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038268
[TBL] [Abstract][Full Text] [Related]
19. Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum β-lactamase.
Lefort A; Chau F; Lepeule R; Dubée V; Kitzis MD; Dion S; Fantin B
Int J Antimicrob Agents; 2014 Apr; 43(4):366-9. PubMed ID: 24388117
[TBL] [Abstract][Full Text] [Related]
20. Potential role of fosfomycin in the treatment of community-acquired lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Wilson DT; May DB
Am J Ther; 2013; 20(6):685-90. PubMed ID: 21768870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
